The Potential of PCI

PCI is uniquely positioned to significantly impact the three pillars of oncology drug development: chemotherapy, immuno-oncology, nucleic-acid based therapies.

These three anti-cancer treatment paradigms require access to the inside of their human target cells, e.g. tumour cells or immune cells, in order to be effective. Unfortunately, many of these substances are by nature encapsulated in so-called endosomes as they enter the target cell. Once inside the cell, most of the active compound may hence be trapped in the endosomes and therefore unable to exert its therapeutic effect. Pharmaceutical companies around the world struggle to find effective methods to release drugs that are entrapped in this way, and are actively searching for technologies that provide adequate drug release inside the target cells, in order to exploit the full therapeutic and commercial potential of their products.

PCI Biotech’s patented investigational drug fimaporfin is able to unlock the intracellular capsules (endosomes) where the active compounds are entrapped. Hence, fimaporfin has the ability to unlock the true potential of new promising classes of cancer therapy, such as certain immunotherapeutics, RNA therapeutics , as well as established chemotherapies.

PCI Biotech’s lead fimaChem programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising Field.